JP2022512734A5 - - Google Patents
Info
- Publication number
- JP2022512734A5 JP2022512734A5 JP2021521141A JP2021521141A JP2022512734A5 JP 2022512734 A5 JP2022512734 A5 JP 2022512734A5 JP 2021521141 A JP2021521141 A JP 2021521141A JP 2021521141 A JP2021521141 A JP 2021521141A JP 2022512734 A5 JP2022512734 A5 JP 2022512734A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- bispecific antibody
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024086669A JP2024123004A (ja) | 2018-10-17 | 2024-05-28 | エキソソーム標的化二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746862P | 2018-10-17 | 2018-10-17 | |
| US62/746,862 | 2018-10-17 | ||
| PCT/US2019/056698 WO2020081786A1 (en) | 2018-10-17 | 2019-10-17 | Exosome-targeting bispecific antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086669A Division JP2024123004A (ja) | 2018-10-17 | 2024-05-28 | エキソソーム標的化二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512734A JP2022512734A (ja) | 2022-02-07 |
| JP2022512734A5 true JP2022512734A5 (https=) | 2022-10-17 |
| JP7496818B2 JP7496818B2 (ja) | 2024-06-07 |
Family
ID=70284767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521141A Active JP7496818B2 (ja) | 2018-10-17 | 2019-10-17 | エキソソーム標的化二重特異性抗体 |
| JP2024086669A Abandoned JP2024123004A (ja) | 2018-10-17 | 2024-05-28 | エキソソーム標的化二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024086669A Abandoned JP2024123004A (ja) | 2018-10-17 | 2024-05-28 | エキソソーム標的化二重特異性抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210347895A1 (https=) |
| EP (1) | EP3866851A4 (https=) |
| JP (2) | JP7496818B2 (https=) |
| KR (1) | KR20210091714A (https=) |
| CN (1) | CN113423425A (https=) |
| AU (1) | AU2019359877A1 (https=) |
| BR (1) | BR112021007469A2 (https=) |
| CA (1) | CA3116560A1 (https=) |
| IL (1) | IL282355A (https=) |
| MX (1) | MX2021004036A (https=) |
| SG (1) | SG11202103812RA (https=) |
| WO (1) | WO2020081786A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022501062A (ja) | 2018-10-02 | 2022-01-06 | イムノーム、インコーポレイテッド | Ｅｐｎ１を標的とする抗体 |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| CN114354913B (zh) * | 2021-12-31 | 2024-07-19 | 厦门大学 | 一种外泌体pd-l1糖基化检测方法 |
| CN114990129B (zh) * | 2022-05-11 | 2023-02-03 | 北京贝来生物科技有限公司 | 表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用 |
| WO2023225613A2 (en) * | 2022-05-18 | 2023-11-23 | Immunome, Inc. | Combination anti-epn1 and anti-pd-l1 antibody therapies |
| EP4630966A2 (en) * | 2022-12-09 | 2025-10-15 | The Regents of the University of California | Intelligent design and engineering of proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20160145355A1 (en) * | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| EP4141032B1 (en) * | 2014-11-20 | 2024-05-29 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| RU2018105846A (ru) * | 2015-07-29 | 2019-08-28 | Новартис Аг | Комбинация антагониста pd-1 с ингибитором egfr |
| WO2017087280A1 (en) * | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| US11421028B2 (en) * | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| PT3433273T (pt) * | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| CN108250302A (zh) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | 一种多功能蛋白质 |
-
2019
- 2019-10-17 KR KR1020217014855A patent/KR20210091714A/ko not_active Ceased
- 2019-10-17 AU AU2019359877A patent/AU2019359877A1/en not_active Abandoned
- 2019-10-17 CA CA3116560A patent/CA3116560A1/en active Pending
- 2019-10-17 SG SG11202103812RA patent/SG11202103812RA/en unknown
- 2019-10-17 CN CN201980081663.1A patent/CN113423425A/zh active Pending
- 2019-10-17 JP JP2021521141A patent/JP7496818B2/ja active Active
- 2019-10-17 BR BR112021007469-4A patent/BR112021007469A2/pt not_active IP Right Cessation
- 2019-10-17 US US17/283,614 patent/US20210347895A1/en not_active Abandoned
- 2019-10-17 MX MX2021004036A patent/MX2021004036A/es unknown
- 2019-10-17 WO PCT/US2019/056698 patent/WO2020081786A1/en not_active Ceased
- 2019-10-17 EP EP19872880.0A patent/EP3866851A4/en not_active Withdrawn
-
2021
- 2021-04-14 IL IL282355A patent/IL282355A/en unknown
-
2024
- 2024-05-28 JP JP2024086669A patent/JP2024123004A/ja not_active Abandoned